These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Anthraquinones from the roots of Knoxia valerianoides inhibit the formation of advanced glycation end products and rat lens aldose reductase in vitro.
    Author: Yoo NH, Jang DS, Lee YM, Jeong IH, Cho JH, Kim JH, Kim JS.
    Journal: Arch Pharm Res; 2010 Feb; 33(2):209-14. PubMed ID: 20195820.
    Abstract:
    Eight known compounds, lucidin (1), lucidin-omega-methyl ether (2), rubiadin (3), damnacanthol (4), 1,3,6-trihydroxy-2-methoxymethylanthraquinone (5), 3,6-dihydroxy-2-hydroxymethyl-9,10-anthraquinone (6), 1,3,6-trihydroxy-2-hydroxymethyl-9,10-anthraquinone 3-O-beta-primeveroside (7), and vanillic acid (8), were isolated from EtOAc- and n-BuOH-soluble fractions of the roots of Knoxia valerianoides. The structures of 1-8 were identified by analysis of spectroscopic data as well as by comparison with published values. All the isolates were subjected to in vitro bioassays to evaluate advanced glycation end products (AGEs) formation and rat lens aldose reductase (RLAR) inhibitory activity. Compound 5 showed the most potent inhibitory activity (IC(50) = 52.72 microM) against AGEs formation. Compounds 1, 2, and 8 also showed potent inhibitory activity on AGEs formation with IC(50) values of 79.28, 62.79, and 93.93 microM, respectively, compared with positive control, aminoguanidine (IC(50) = 962 microM). While, compounds 1 and 5-7 showed strong inhibitory activity against RLAR with IC(50) values of 3.35, 3.04, 6.39, and 2.05 microM, respectively.
    [Abstract] [Full Text] [Related] [New Search]